VR Logo

Zogenix Inc (ZGNX) download report


Healthcare | Biotechnology & Pharma Research

Zogenix Inc (ZGNX) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States.

IPO Date: 23-Nov-2010

Co-Founder, CEO, Pres & Director: Dr. Stephen J. Farr

Exec. VP, CFO & Treasurer: Mr. Michael P. Smith

Listing: NASDAQ: ZGNX

Country: United States

Headquarters: EmeryVille, CA

Website: https://www.zogenix.com

Key Facts

Market cap: $1,500.17 Mln

Revenue (TTM): $81.69 Mln

Earnings (TTM): $-227.41 Mln

Cash: $301.72 Mln

Total Debt: $168.48 Mln

Insider's Holding: 0.68%

Liquidity: Low

52 Week range: $11.03 - 26.90

Shares outstanding: 56,228,300

10 Years Aggregate:

  • CFO: $-967.31 Mln
  • EBITDA: $-1,229.02 Mln
  • Net Profit: $-1,270.25 Mln

Stock Performance

Time Period Zogenix Inc (ZGNX) S&P BSE Sensex* *
YTD64.18-9.49--
1 month2.26-2.87--
3 months114.81-8.59--
1 Year28.640.81--
3 Years-19.3910.39--
5 Years22.5611.11--
10 Years2.1312.00--
As on 07-Mar-2022 *As on 24-Jun-2022
Year Zogenix Inc (ZGNX) S&P BSE Sensex S&P BSE Sensex
2021-18.7121.9921.99
2020-61.6515.7515.75
201942.9814.3814.38
2018-8.925.875.87
2017229.6327.9127.91
2016-17.571.951.95
201534.49-5.03-5.03